logo

CGEM

Cullinan
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 1
consensus rating "Strong Buy"
EPS Below Expectations

Key Stats

--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--

About CGEM

Cullinan Therapeutics, Inc.

A biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer

Pharmaceutical
Invalid Date
01/08/2021
NASDAQ Stock Exchange
111
12-31
Common stock
One Main Street, Suite 520, Cambridge, MA 02142
--
Cullinan Therapeutics, Inc., is incorporated in Delaware. The company is a biopharmaceutical company focused on developing a diverse pipeline of tumor-targeted therapies and immuno-oncology therapies with translational potential for cancer patients.

Company Financials

EPS

CGEM has released its 2024 Q4 earnings. EPS was reported at -0.73, versus the expected -0.74, beating expectations. The chart below visualizes how CGEM has performed over recent quarters, highlighting trends in earnings surprises.

Forecast

Wall Street Opinions

Price Target

Volume Profile

Trade Flow Insight

Seasonals

Community Forum

Loading...

Related News

No articles available

Related Symbols

You can ask Aime